|
|
News Breaks
|
December 29, 2011
|
| 08:07 EDT |  | PPHM |
| theflyonthewall.com: | Peregrine provides update on HCV clinical program | | Peregrine Pharmaceuticals provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus, HCV...The goals of the study were to determine if bavituximab plus ribavirin has a better safety profile as compared to interferon plus ribavirin, to confirm that the combination of bavituximab and ribavirin has antiviral activity defined as 12 week early virologic response (EVR)(1) and to compare antiviral activity of peg-interferon plus ribavirin versus bavituximab plus ribavirin...A preliminary data analysis indicates that the combination of bavituximab and ribavirin appeared safe and well tolerated with patients reporting fewer side effects than in the interferon-containing arm. Initial data from the study also indicated that both dose levels of bavituximab with ribavirin demonstrated antiviral activity, however the antiviral effects in patients receiving the 0.3 mg/kg dosing level were more pronounced...More patients had achieved EVR in the interferon-containing group by the end of the study, however based on the nature of late EVR development in the bavituximab containing arms at the very end of the 12 week trial, a longer-term evaluation is needed to adequately compare the effectiveness of bavituximab and interferon. The company plans to present full results from the study at a medical conference in 2012. :theflyonthewall.com |
|
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 21, 2012
|
| 09:00 EDT |  | PPHM |
| | 07:36 EDT | | PPHM |
|
|
|
|
|
Subscribe for More Information